Last reviewed · How we verify
NB-001 (0.3%)
NB-001 is a nanoemulsion formulation designed to deliver antimicrobial or antiviral agents topically with enhanced penetration and bioavailability.
At a glance
| Generic name | NB-001 (0.3%) |
|---|---|
| Sponsor | NanoBio Corporation |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
NanoBio Corporation's NB-001 utilizes nanoparticle technology to create a stable emulsion that improves drug delivery across biological barriers. The 0.3% formulation suggests a topical or mucosal application intended to maximize local therapeutic effect while minimizing systemic exposure. This approach is characteristic of NanoBio's platform for enhancing penetration of active pharmaceutical ingredients.
Approved indications
Common side effects
Key clinical trials
- NB-001 Treatment of Recurrent Herpes Labialis (PHASE3)
- A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis (PHASE3)
- A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis (SHaRCS) (PHASE3)
- Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |